Progyny: Long-Term Thesis Still Intact
Progyny's stock is trailing the S&P 500 thus far in 2024 amongst macro concerns such as the Alabama court ruling on frozen embryos. However, Progyny's Q4 2023 revenue grew by 26%, and the company c...
Progyny Stock Is Falling After Earnings. What the IVF Ruling Means for It.
Shares of fertility-solutions firm Progyny are in the red on disappointing guidance. The company says the Alabama court ruling on in vitro fertilization won't affect it.
Progyny, Inc. (PGNY) Q4 2023 Earnings Call Transcript
Progyny, Inc. (PGNY) Q4 2023 Earnings Call Transcript
Progyny Inc.: Resilient Business Model With Strong Growth Ahead
Progyny, Inc. demonstrates strong resilience and sustained growth potential in a weak macro backdrop. The company's revenue grew 37% year-over-year, beating estimates, with strong performance in fe...
Progyny (PGNY) is an Incredible Growth Stock: 3 Reasons Why
Progyny (PGNY) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Progyny, Inc. to Present at Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum
NEW YORK, Nov. 10, 2023 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a leading benefits management company specializing in fertility and family building benefits solutions, today announced tha...
Progyny: 4 Reasons I Bought This Stock
There are several clear reasons to consider Progyny stock. The company's worth is overlooked, making it a sneaky value play for investors. Here's how Progyny's unique position in the industry and f...
3 Reasons Growth Investors Will Love Progyny (PGNY)
Progyny (PGNY) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Here is Why Growth Investors Should Buy Progyny (PGNY) Now
Progyny (PGNY) could produce exceptional returns because of its solid growth attributes.
Related Companies